Related Experiment Video
Updated: Sep 29, 2025
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
Published on: September 30, 2021
Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A
Kun Huang1, Yan Wang2, Yingzi Zhen3
1Hematology Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China, 100045; Hematologic Disease Laboratory, Hematology Center, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, China, 100045.
Insights
This study on Kovaltry (BAY81-8973) in Chinese pediatric hemophilia A patients found significant pharmacokinetic variability. Individualized treatment is crucial, as blood type and VWF levels impact drug effectiveness and bleeding rates.
Area of Science:
- Hematology
- Pharmacology
- Pediatrics
Background:
- Kovaltry (BAY81-8973) is a common hemophilia A treatment in China.
- Individualized pharmacokinetics (PK) and clinical outcomes are not well-established in this population.
Purpose of the Study:
- To investigate the pharmacokinetics (PK) and clinical outcomes of Kovaltry (BAY81-8973) in Chinese pediatric patients with severe hemophilia A.
- To explore factors influencing PK variability and their correlation with clinical outcomes.
Main Methods:
- Sixty-one pediatric patients with severe hemophilia A received a single 50 IU/kg dose of Kovaltry.
- PK parameters were analyzed using WinNonlin software.
- Bleeding rates were assessed via routine records, and joint status was evaluated using ultrasound.
Main Results:
- Significant inter-individual variability in PK parameters (half-life, clearance) was observed.
- Blood group O patients had shorter half-lives and higher clearance compared to non-O patients.
- Higher VWF:Ag levels correlated with longer half-life and lower clearance.
- Higher trough levels were associated with decreased bleeding rates, though not universally predictive.
- Inconsistencies were noted between reported joint bleeds and ultrasound findings.
Conclusions:
- There is substantial inter-individual variability in Kovaltry pharmacokinetics, clinical bleeding patterns, and joint vulnerability in Chinese pediatric hemophilia A patients.
- These factors necessitate individualized treatment strategies for optimal patient management.
- Further research may clarify the predictive value of trough levels and improve joint assessment accuracy.
Introduction:
As the most commonly used FVIII concentrate in China, the individualized pharmacokinetics (PK) and clinical outcomes of Kovaltry (BAY81-8973) are not fully investigated in this population.
Materials And Methods:
Pediatric patients with severe hemophilia A were enrolled in Beijing Children's Hospital. After a three-day washout, they received PK tests after a single-dose infusion of 50 IU/kg. The blood samples were collected with a six-point assay. One-stage-based activated partial thromboplastin time was used for FVIII activity. The PK parameters were generated by WinNonlin software. The bleeding rates were calculated by their routine therapy record. The ultrasound was used to evaluate their both sides of knees, elbows and ankles.
Result:
Sixty-one boys with severe hemophilia A were enrolled and their median age was 5.73 years. Twenty-nine of them were blood group-O. Compared with blood group-O patients, those non-O patients showed longer t1/2 (15.26 vs. 13.03 h, P < 0.001) and reduced CL (3.04 vs. 3.66 mL/kg/h, P < 0.05). Patients with higher VWF:Ag level had longer half-life time (t1/2) (r = 0.60, P < 0.0001) and lower clearance (CL) (r = -0.45, P < 0.001). Patients with higher trough level showed decreased bleeding rates compared with those owning a trough level below 1 IU/dL (P < 0.05). In general, the zero bleeding rates raised with elevation of trough level. However, 20-30% of patients with low trough level (<1 IU/dL) also showed no bleeds and 10-20% of patients with high trough level (>5 IU/dL) still suffer bleeds. An inconsistency of 28% between joint bleeds and ultrasound evaluation was showed.
Conclusion:
This study revealed the great inter-individual variability in PK parameters, clinical bleeding phenotype and joint vulnerability, which all should be considered in treating hemophilia A.
Related Concept Videos
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
01:21Factors Affecting Drug Response: Overview
01:12Analysis of Population Pharmacokinetic Data
01:27Nonlinear Pharmacokinetics: Role of Transporters
Polymorphisms occurring in drug transporters can alter...